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a b s t r a c t
Breast cancer is the most common cancer that majorly affects female. The present study is focused on
exploring the potential anticancer activity of 2-((1, 2, 3, 4-Tetrahydroquinolin-1-yl) (4 methoxyphenyl)
methyl) phenol (THMPP), against human breast cancer. The mechanism of action, activation of specific
signaling pathways, structural activity relationship and drug-likeness properties of THMPP remains elu-
sive. Cell proliferation and viability assay, caspase enzyme activity, DNA fragmentation and FITC/Annexin
V, AO/EtBr staining, RT-PCR, QSAR and ADME analysis were executed to understand the mode of action of
the drug. The effect of THMPP on multiple breast cancer cell lines (MCF-7 and SkBr3), and non-
tumorigenic cell line (H9C2) was assessed by MTT assay. THMPP at IC50 concentration of 83.23 lM
and 113.94 lM, induced cell death in MCF-7 and SkBr3 cells, respectively. Increased level of caspase-3
and -9, fragmentation of DNA, translocation of phosphatidylserine membrane and morphological changes
in the cells confirmed the effect of THMPP in inducing the apoptosis. Gene expression analysis has shown
that THMPP was able to downregulate the expression of PI3K/S6K1 genes, possibly via EGFR signaling
pathway in both the cell lines, MCF-7 and SkBr3. Further, molecular docking also confirms the potential
binding of THMPP with EGFR. QSAR and ADME analysis proved THMPP as an effective anti-breast cancer
drug, exhibiting important pharmacological properties. Overall, the results suggest that THMPP induced
cell death might be regulated by EGFR signaling pathway which augments THMPP being developed as a
potential candidate for treating breast cancer.
 2020 The Author(s). Published by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Breast cancer is the most challenging type of cancer worldwide.
In 2018, about 2.1 million new breast cancer cases have been diag-
nosed. In over 100 countries, it ranks as the leading causes of can-
cer death (Bray et al., 2018). Estrogen receptors (ER) are
responsible for approximately 70–75% of inter-tumor heterogeneic
nature of breast cancer. Estrogens on binding to ER is responsible
for the transcription/expression of many growth factors involving
cellular proliferation (Sun et al., 2001). Apart from estrogens, there
are many non-steroidal growth factors including EGF and IGF1,
that can bind to ER and stimulate proliferation via signal transduc-
tion pathways like MAPK pathway (Kato et al., 1995). Progesterone
receptor (PR) also plays an equal importance in cancer develop-
ment and progression as ER.
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The treatment regimens followed in ER+/PR+ breast cancer
cases are mostly hormonal/endocrine therapy. It is done by block-
ing the ER, in-turn controlling the growth promoting effects on the
cell. Though, it is recognized as an effective treatment for ER+/PR+
patients, most of the patience develops resistance to such thera-
pies. There is a vital need for the novel therapies over the existing
hormonal therapies, thereby extending the progression period,
eliminating or reducing the resistance and postpone the
chemotherapy (Ciruelos Gil, 2014).
In accordance with this, our research group indulges in synthe-
sis of novel small molecule drugs for multiple cancer treatments.
One such phenolic derivatives is, 2-((1, 2, 3, 4-
Tetrahydroquinolin-1-yl) (4 methoxyphenyl) methyl) phenol
(THMPP), found to have good cytotoxicity activity against bone
carcinoma cells (Karjalainen et al., 2017). We hypothesize that
THMPP might have anticancer activity against breast cancer and
hence we wish to explore the mechanism of its action of the com-
pound THMPP against breast cancer cells.
The present study also signifies that THMPP can induce cell
death in breast cancer cells via EGFR signaling pathway. The EGFR
overexpressed in metastatic breast cancer cells that influences the
downstream signaling pathways such as the ERK MAPK, PI3K-AKT,
SRC, PLC-c1-PKC, JNK, and JAK-STAT pathways. The PI3K/AKT/
mTOR pathway is the well-known signaling pathway involved in
cell proliferation and survival. In tumorigenesis, this signal cascade
is continuously activated even in the absence of any growth fac-
tors/ligands. Inhibition of this pathway can suppress the tumor
growth and eventually benefit the ER+ patient through endocrine
therapy (Martelli et al., 2010). Hence, we also propose to investi-
gate the effect of THMPP in the regulation of PI3K signaling path-
way genes in combination with computational analysis.
2. Materials and methods
2.1. Cell lines and culture
Human breast adenocarcinoma cell lines, MCF-7, SkBr3; Triple
negative breast cancer cells, MDAMB-231; and rat myoblast cells,
H9C2, were obtained from NCCS, Pune. All the cell lines used in the
studywasEGFR (+). Cellswere cultured inDulbecco’sModifiedEagle
Medium(DMEM), supplementedwith10%Fetal BovineSerum(FBS),
maintained at 37 C humidifiedwith 5% CO2 (Vaiyapuri et al., 2015).
THMPP (Fig. 1a) was synthesized by our research group as previ-
ouslydescribed.Untreated cellswereusedas anegative controlwith
cyclophosphamide, as a positive control (Fig. 1b). The characteriza-
tion of the chemical compound and the preparation of THMPP was
described in the previously established procedure (Doan et al.,
2019, 2017). NMRspectroscopic data of the compoundwas included
as the supplementary file (Supplementary file 1).
2.2. Cytotoxicity assay
The cytotoxicity potential of THMPP against the growth of
breast cancer cells were analyzed using MTT assay (Mosmann,
1983). The cell density of 1.2  104 cells/well were plated in 96
well plates and maintained at 37 C overnight. Cells were treated
with varying concentrations of the samples (10, 25, 50, 75 and
100 mM) for 24 h, followed by the addition of 100 ml medium with
10 ml of MTT (5 mg/ml). As a comparative study, MDAMB-231 cells
were also treated with 10 mM concentration of THMPP. H9C2, non-
tumorous cells were used as a control cell line and treated with the
lower concentration of 10 mM and higher concentration of 100 mM
THMPP. The medium was discarded after 4 h of treatment and the
formazan crystals was dissolved using 100 ml of DMSO. The purple
color developed was read using microtiter plate reader at 570 nm.
Cyclophosphamide was used as the positive control and the cells
with the medium (untreated) serves as a control. Cell viability
was calculated using the following formula:
Viability % ¼ Test OD
Control OD
 
 100; Cytotoxicity %
¼ 100 Viability%:
2.3. Caspases 3 and 9 activity
Caspase-3 and -9 activities were measured by colorimetric
assay kit, following the manufacturer’s protocol (Calbiochem, Mer-
ck). Treated cells were lysed using the buffer containing 50 mM
HEPES, 100 mM NaCl, 0.1% CHAPS, 1 mM DTT, 100 mM EDTA
and centrifuged at 10000 rpm for 1 min. The extracts were care-
fully collected, and the protein concentration was estimated by
Bradford’s assay. Approximately, 100–200 mg of protein for each
assay was prepared by lysing the cell with 50 ml cell lysis buffer
and incubated in 96-well plates with 5 ml of the 4 mM p-
nitroanilide (pNA) substrates, DEVD-pNA for 2 h at 37 C. The
Caspase-3 and -9 activities were analysed by measuring the
cleaved substrate to free pNA at 405 nm in a microplate reader.
The relative level of Caspase-3 and -9 were quantified using the
ratio of the absorbance of THMPP treated to untreated cells.
2.4. DNA fragmentation
To study the effect of the compound in apoptosis induction in
breast cancer cells, DNA of MCF-7 cells were subjected to elec-
trophoresis. Briefly, MCF-7 cells were lysed using 100 ml of cell lysis
buffer for one hour at room temperature, and the cell debris was
removed by centrifugation for 15 min at 3000 rpm at 4 C. The
supernatant was then mixed with equal volume of phenol: chloro-
form: isoamyl alcohol mixture, and then centrifuged at 5000 rpm
for 15 min. The DNA was precipitated on adding 40 ml of 3.5 M
ammonium acetate and ice-cold isopropanol to the aqueous phase
and incubated at 20 C for 1 h. The sample was centrifuged at
10000 rpm for 15 min and the pellet was washed with 70% ethanol
and stored in 20–50 ml of TE buffer. DNA samples were elec-
trophoresed at 50 V in 2% agarose gel (w/v). DNA was detected
using EtBr staining under UV light along with DNA ladder (1 kb)
as control (Basnakian and James, 1994).
2.5. RNA extraction and CDNA synthesis
Total cellular RNA from both the untreated and treated MCF-7
cells were extracted using ONE STEP-RNA Reagent (Bio Basic
Canada Inc.). This method is an improved version of single-step
RNA isolation using phenol and guanidine isothiocyanate
(Chomzynski and Sacchi, 1987). RNA pellet was extracted and vac-
uum dried for 5–10 min, dissolved in DEPC treated water and
stored at 20 C. The isolated RNA (1–2 mg) was immediately
reverse transcribed using EasyScript PlusTM Reverse Transcriptase
primed using oligo-dT. The reaction mixture consists of 1–2 mg of
RNA, 2 ml oligo-dT (stock 10 mM), with the total volume of 12.5 ml
with DEPC-treated water. The mixture was incubated at 65 C for
5 min and 1X reverse transcriptase buffer, 2.5 mM of dNTP mix,
and 40 U/ml of RNase inhibitor were added in specified order.
Finally, 1 ml of Easy Script reverse transcriptase (200 U/ml) was
added after 5 min of incubation at 42 C. The final reaction was
set up at 42 C for 50 min, heated up to 70 C for 10 min and chilled
on ice (Chomzynski and Sacchi, 1987).
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2.6. Reverse transcription polymerase chain reaction (RT-PCR) analysis
Amplification of the target genes EGFR, PI3K, S6K1 and b-actin
were achieved using specific forward and reverse primers. b- actin,
that shows the constitutive expression was used as a control for
the gene expression analysis. The primers for the target mRNA
were used as follows: EGFR, Fw: 50- TCCCCGTAATTATGTGGT GACA
GATC-30 and Rv: 50-ACCCCTAAATGCCACCGGC-30 with the amplicon
size 250 bp; PI3K, Fw: 50-AACACAGAAGACCAATACTC-30 and Rv: 50-
TTCGCCATCTACCACTAC-30 with the amplicon size of 195 bp; S6K1,
Fw: 50-CACATAACCTGTGGTCTGTTGCTG-30 and Rv: 50- AGA TGCA
AAGCGAACTTGGGATA-30 with the amplicon size of 180 bp; and
for reference gene b- actin, Fw: 50-CACCCGCGAGTACAACCTT-30
and Rv: 50-CCCATACCCACCATCACACC-30 with the amplicon size
of 204 bp, were synthesized and used further for PCR reactions.
The PCR reaction was setup using the following reagents: 1X
Taq Buffer (with MgCl2), 0.2 mM dNTPs, 2.5 mMMgCl2, 0.3 mM for-
ward and reverse primer, template cDNA (10% of the reaction) and
1U Taq Polymerase. Amplification was performed with the follow-
ing PCR conditions: initial denaturation at 94C for 2 min and 32
cycles of 94C for 30 s, Ta for 1 min, 72C for 1 min 20 s with the
final extension at 72C for 7 min. Ta was specifically optimized
for each gene such as 56C for EGFR, 54C for PI3K, 56C for S6K1
and 54C for b- actin. The amplicons were separated on 1.5% agar-
ose gel with 100 bp ladder was as a marker at 50 V for 90 min.
Image J software was used to quantify the band intensity.
2.7. FACS analysis
FACS analysis was performed to check the apoptotic induction
in MCF-7 cells after treatment with THMPP using FITC Annexin V
(Vermes et al., 1995). FITC Annexin V stained cells negative to pro-
pidium iodide (PI) represents apoptotic cells, FITC Annexin V/PI
stained cells represents late apoptosis/ necrotic cells, whereas FITC
Annexin V/PI negative cells represents live cells (Koopman et al.,
1994). MCF-7 cells (1  105 cells/sample) were treated with the
IC50 concentration of THMPP and 5 ml of FITC Annexin V and 5 ml
PI were added and then incubated for 15 min at 25 C in the dark.
Binding buffer (1X) was added to each sample and subjected to
flow cytometry analysis. The cells were acquired and gated by
FITC-A and PE-A. All the measurements were performed within
1 h under similar settings in the equipment.
2.8. ACRIDINE orange/ethidium bromide (AO/ETBR) staining
Apoptosis induction by THMPP in MCF-7 was identified by AO/
EtBr dual staining. As explained previously, MCF-7 cells were trea-
ted with varying concentrations of THMPP, 78.23 mM, 83.23 mM
and 88.23 mM with the control well left untreated. The cells were
incubated for 24 h and trypsinised. It was centrifuged, and the pel-
let was suspended in PBS. To 25 ll of the supernatant solution,
25 ll of staining solution containing 1:1 mixture of 100 lg/ml
AO and 100 lg/ml EB was added. The cell suspension (10 ll) was
observed under fluorescent microscope using blue (420–495 nm)
and green filter (510–560 nm) and at least 300 cells/well was used
for quantification in different fields (Basikc et al., 2006; Chowdhury
et al., 2012).
2.9. Molecular docking using gold
Automated docking for THMPP against EGFR was performed
using the genetic algorithm GOLD (Version 3.2 CCDC, Cambridge,
Fig. 1. Cytotoxicity effect of THMPP in different breast cancer cell lines. (a) and (b)- Ligand structure: 2D structure of THMPP and CP. IUPAC:  2-((1, 2, 3, 4-
Tetrahydroquinolin-1-yl) (4 methoxyphenyl) methyl) phenol and N,N-bis(2-chloroethyl)-2-oxo-1,3,2k5-oxazaphosphinan-2-amine, respectively; M. wt – 329.443 and
261.083. The phase contrast microscopic images of MCF-7 cell line (c) untreated and (d) treated. Cell cytotoxicity of THMPP in different cell lines by MTT assay (e) MCF-7 cells
(f) SkBr3 cells at different concentration (10 mM, 25 mM, 50 mM, 75 mM and 100 mM) and (g) Treatment of H9C2 cells with10mM and 100 mM of THMPP. Cyclophosphamide was
used as a positive control; (h) Percentage of growth inhibition in multiple breast cancer cell lines and non-tumorous cells treated with 10 mM THMPP. Data points and error
bars represent mean ± S.E.M (n = 3 per group). Statistical significance was assumed for p-values *P < 0.0001.
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UK) (Jones et al., 1997b). It has been validated earlier with a data
set containing 300 protein-ligand complexes retrieved from PDB
(Manikandan and Malik, 2008). To explore the ligand conformation
and rotational flexibility of selected receptor, GOLD program
makes use of genetic algorithm (GA). Grid box not exceeding
10 Å in size was chosen and the coordinates of the enclosing box
(x = 121 Å; y = 87 Å; z = 45 Å) were also described from the active
residues. Maximum of 10 different structural conformations for
docking was examined and the highest binding conformers were
selected for further analysis (Nissink et al., 2002).
2.10. QSAR analysis of THMPP
A quantitative structure-biological activity-property relation-
ship (QSAR) approach was performed to quantitatively depict
and provide mechanistic insights into interactions between the
chemical structures of THMPP by considering the compounds with
similar structures. QSAR is used for testing the relationship
between the molecular descriptors of the set of compounds of
interest with their respective biological activity (Roy et al., 2015).
Here, 32 compounds were selected which share a significant struc-
tural similarity with the THMPP. In addition, biological activity in
terms of IC50 were also collected from the literature (Table 1).
The Dragon software calculates the descriptors for the compounds,
which has about 1497 descriptors, that are classified into 18
groups. Each molecule in the training set were found to have set
of 18 descriptors (Todeschini and Gramatica, 1997). Set of descrip-
tors that are most appropriate to the IC50 of the compounds were
selected for further analysis, and the MLR models were built and
QSAR equations eliminating the variables were established using
BUILDQSAR software.
2.11. ADMET analysis
The various pharmacokinetics properties and physiochemical
properties of the compound, THMPP were calculated using ADMET
descriptors. ADMET can provide metabolic interactions of the drug
by profiling its Absorption, Distribution, Metabolism, Excretion and
Toxicity properties. The prediction will contain the following
important ADMET descriptors such as Blood-Brain Barrier penetra-
tion, Human Intestinal Absorption, CYP450 2C9, Caco-2 cell perme-
ability and Ames test. The drug likeliness score of the compound
determines the potentiality of the compound.
3. Results
3.1. THMPP induced cytotoxicity effect
To evaluate the effect of THMPP against the human breast can-
cer cell lines MCF-7 and SkBr3 and the non-cancerous mouse myo-
blast cells H9C2, the percentage of cell proliferation/cell viability
was measured using MTT assay. The phase contrast microscopic
images of the treated and untreated MCF-7 cells are represented
in Fig. 1c and d. THMPP showed a dose-dependent increase in
the cytotoxicity against MCF-7 cells and SkBr3 (Fig. 1e and f).
The toxicity of THMPP against MCF-7 and SkBr3 cells was found
to be 36.47%, 53.98% and 18.86%, 40.47% at 10 lM and 100 lM,
respectively. The IC50 concentration of THMPP against was less in
MCF-7 with 83.23 mM than SkB3 cells with 113.94 mM (Fig. 1e
and f). Cyclophosphamide was used as a positive control, where
its cytotoxicity against MCF-7 and SkBr3 was significantly high.
The IC50 value of CP against MCF-7 and SkBr3 was found to be
42.79 mM and 38.34 mM, respectively (Fig. 1e and f). Also, THMPP
Table 1
List of training set and test set compounds with its IC50 values.
Training Set
S.No Compound Name IC50 References
1 2-((1,2,3,4-tetrahydroquinolin-1-yl)(4-methoxyphenyl)methyl)phenol 83.23 Present Study
2 Curcusone B 0.2 Sawadogo et al., 2012
3 Curcusone C 0.08
4 Curcusone D 0.1
5 voruscarin 4
6 Uscharin 4
7 2-Hydroxy-isojatrogrossidion 0.2
8 2-epi-hydroxyisojatrogrossidion 0.2
9 Multidione 5.5
10 4Z jatrogrossidentadion 0.6
11 4E jatrogrossidentadion 2.1
12 Pinostrobin 10.2
13 Balanitin-6/7 2.6
14 Jatropholone 7.5
15 Multi-substituent phenyl derivatives 1 1.38 Tao et al., 2010
16 Multi-substituent phenyl derivatives 4 11.74
17 Mangrove-derived quinones 7 0.17
18 Mangrove-derived quinones 8 2.53
19 Mangrove-derived quinones 9 1.43
20 Mangrove-derived quinones 11 13.23
21 Mangrove-derived quinones 13 16.32
Test Set
S.No Compound Name IC50 References
1 Mangrove-derived quinones 14 35.23 Tao et al., 2010
2 Mangrove-derived quinones 18 17.22
3 Isoflavone analog 78 19.77
4 Fatty acid derivatives 81 0.41
5 Phytol 34 Malek et al., 2008
6 phenolic constituents 4 62.9 El Molla et al., 2016
7 phenolic constituents 6 63.8
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has least percentage of cytotoxicity to non-cancerous cells, H9C2
(0.91%) when compared with other breast cancer cell lines such
as MCF-7(36%), SkBr3(18%) and MDAMB-231(30%) upon treatment
with 10 mM of THMPP (Fig. 1g and h). These results suggested that
THMPP has the ability to specifically target breast cancer cell lines
than the normal cells. The differences in the treated conditions was
found to be statistically significant as per two-way ANOVA (P-val
ue < 0.0001).
3.2. Caspase-3 and caspase-9 induction
To clarify whether THMPP could induce apoptosis, caspase-3
and -9 activities were measured in MCF-7 and SkBr3. The cells
were treated with the respective IC50 concentration of THMPP. In
both the cell lines, there was significant fold change in the enzyme
activity after the treatment. In MCF-7 cells, it was found that the
caspase-3 and -9 activities were increased by a fold level of 0.17
and 0.47, whereas in SkBr3, fold change of 0.07 and 0.25 was
observed respectively, when compared to the untreated cells
(Fig. 2a and b). Thus, THMPP could activate caspase enzyme activ-
ity, thereby induces apoptosis in both the cell lines. The values
were statistically significant, as per two-way ANOVA test
(P < 0.0001).
3.3. Induction of DNA strand break by THMPP
To further substantiate the ability of THMPP in inducing apop-
tosis, the cells were subjected for DNA fragmentation assay. The
DNA fragmentation is a sign of apoptosis, which causes nicks in
genomic DNA of the cells (Eastman and Barry, 1992). The genomic
DNA from THMPP treated MCF-7 cells was isolated and analysed
by agarose gel electrophoresis. The result shows that untreated
cells have intact DNA with no laddering whereas treated cells
showed a characteristic ladder of inter-nucleosomal fragmenta-
tion, confirming the induction of apoptosis (Fig. 3a).
3.4. Analysis of apoptosis induction by THMPP using Annexin V/PI
The phosphatidylserine externalization in MCF-7 cells stained
with Annexin V-FITC/PI was quantified by flow cytometry to assess
the apoptotic cell death. The analysis showed that THMPP could
induce apoptosis in a concentration-dependent manner (Fig. 3).
The untreated cells were mostly viable. The cells with compro-
mised membrane were analysed by staining using membrane
impermeable dye, PI. Thus the counter staining with PI and
Annexin V delineates the cells at different cell phase. The cells trea-
ted with THMPP showed 3.21% of early apoptotic cells, 36.02% of
late apoptotic cells and 59.7% viable cells (Fig. 3d). This substanti-
ates the effect of THMPP in apoptosis mediated cell death (Fig. 3b
and c).
MCF-7 cells were treated with a varying doses of THMPP for
24 h, as described in the method section. Apoptotic cell death caus-
ing nuclear fragmentation was assessed upon treatment with vary-
ing concentration of THMPP and the cells were observed under
flourescent microscope (Fig. 4). The dual AO/EB fluorescent stain-
ing qualitatively and quantitatively reveals the morphological
Fig. 2. Caspase-3 and Caspase-9 activity in THMPP treated MCF-7 and SkBr3 cell lines. (a) Relative caspase-3 activity of THMPP treated MCF-7 and SkBr3 compared with the
untreated cells. The results were considered significant (two way ANOVA) in comparison with the untreated group (*, P  0.007). (b) Relative caspase-9 activity of THMPP
treated MCF-7 and SkBr3 compared with the untreated cells. The results were considered significant (two way ANOVA) in comparison with the untreated group (*,
P < 0.0001). Data represents Mean ± SEM (n = 3 experiment).
Fig. 3. DNA fragmentation of MCF-7 cells exposed to THMPP (a) DNA gel electrophoresis of internucleosomal DNA fragmentation in 1.5% Agarose gel upon treatment with
THMPP in MCF-7 cell lines (lane 1) Marker-1 Kb ladder; (lane 2) negative control without treatment; (lane 3) DNA of cells treated with THMPP. Assessment of apoptosis by
FACS of apoptosis in THMPP (IC50  83.23 mM) treated MCF-7 cells measured using FITC-labelled annexin V/PI (b) untreated cells; (c) THMPP treated MCF-7 cells. UL- necrotic
cells, UR- late apoptotic cells, LL - viable cells, LR – early apoptotic cells. (d) Quantitative analysis on the percentage of viable, apoptotic, or necrotic cells by FACS analysis.
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changes in apoptotic cells, with clear distinction between normal
cells, apoptotic cells, and necrotic cells.
The Fig. 4a–d showed the mode of cell death by dual AO/EB
staining. Control cells (untreated MCF-7 cells) are normal healthy
cells with green fluorescent cells having normal cytoplasm and
nuclei morphology, and represents only less than 2% cells in apop-
totic stage. The cells entering early apoptosis appears yellowish
green fluorescence with membrane blebbing and those cells in late
apoptosis appeared orange/red fluorescence. It is observed that
48% of the cells were in apoptotic stage upon treatment with
83.23 mM of THMPP, 61% cells at 88.23 mM and 32% cells at
78.23 mM of THMPP treatment. As the concentration of the com-
pound increases, there is a significant increase in the apoptosis
induction and thus THMPP induces cell death through apoptosis
pathway (Fig. 4e).
3.5. Effect of THMPP on the expression of PI3K and S6K1 genes
To further understand the mechanism of action of THMPP, we
examined the influence of THMPP in PI3K signaling pathway.
Fig. 4. Fluorescence microscopy images of AO-EtBr stained MCF-7 cells after treatment with THMPP. (a) Untreated cells; MCF-7 cells treated with THMPP at different
concentrations (b) 78.23 mM, (c) 83.23 mM and (d) 88.23 mM. The white, yellow and blue arrows are representing viable, early apoptotic, and late apoptotic cells respectively.
(e) percentage of apoptosis at different concentrations, where treatment 1 is 78.23 mM; treatment 2 is 83.23 mM; and treatment 3 is 88.23 mM.
Fig. 5. Gene expression analysis in MCF-7 cell upon THMPP treatment. (a) RT-PCR amplification of b- actin (204 bp), EGFR (250 bp), P13K (195 bp) and S6K1 genes (180 bp).
(Lane 1: 100 bp DNA marker, Lane 2: control (untreated) Lane 3: (PCR amplicon treated with THMPP); (b) Optical density was measured to evaluate the mRNA expression of
EGFR; S6K1; PI3K, with the housekeeping gene b-actin serving as the normalization control. The fold change represented as the expression ratio of the genes. Data points and
error bars represent mean ± S.E.M (n = 3 per group). Statistical significance was assumed for p-values *P < 0.0001. (c) Molecular docking analysis of THMPP with EGFR. The
surface-docking model of THMPP in the EGFR active site. The ligand is represented as sticks; and the protein active sites as lines, hydrogen bond interaction are shown in
dotted lines (Red) and the interacting residues are labelled.
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Semi-quantitative RT-PCR was carried out using primers specific
for EGFR, PI3K and S6K1 genes with b-actin as the reference control.
The genes with respective band size of 204 bp (b-actin), 250 bp
(EGFR), 195 bp (PI3K) and 180 bp (S6K1) were observed clearly in
agarose gel (Fig. 5a). The ImageJ was used to calculate the expres-
sion fold of each gene. EGFR gene expression was not altered upon
THMPP treatment when compared with the untreated cell lines.
But, there occurs a reduced level of altered gene expression level
with 0.5 fold change in both PI3K and S6K1 (Fig. 5b). These results
suggest that the THMPP could induce apoptosis by down regulat-
ing the expression of genes, PI3K and S6KI involved in PI3K/AKT
signalling pathway (Fig. 5b). The values were found to be statisti-
cally significant, as per two way ANOVA test (P-value < 0.0001).
3.6. Molecular docking of THMPP with EGFR
Molecular docking was performed using GOLD (Jones et al.,
1997b). The 3D structure of EGFR was availed from protein data
bank with the PDB ids: 2RGP. Binding compatibility was evaluated
based on the docked energy in kcal/mol (Fig. 5c). The active sites
present in the crystal structure of the five receptors were obtained
from the pdbsum database which was further used for the docking
analysis. The following amino acids are present in the 32 active sites
of EGFR receptors, ie., Leu718, Gly719, Ala722, Val726, Ala743,
Lys745, Met766, Cys775, Arg776, Leu777, Leu788, Thr790,
Gln791, Leu792, Met793, Pro794, Phe795, Gly796, Asp800,
Arg803, Arg832, Leu833, Val834, His835, Arg836, Asp837, Leu844,
Leu862, His888, Lys913, Lys970, Arg977. Many significant interac-
tions were predicted between the ligand (THMPP) and the receptor
(EGFR). The best docking score of 33.02 determines the best inter-
action. The Fig. 5c represents the docking score and residual values
of the interaction.
3.7. THMPP structure activity relationship and its pharmacokinetics
properties
BUILDQSAR was used to predict the anti-cancer potential of the
compound, THMPP. Based on the compounds selected (Table 1), a
QSAR model was built. The regression line was plotted and the
compounds that significantly deviate away were considered as
outliers and excluded from the modelling procedure. The QSAR
model was tested against the compounds in the test set and the
predictability of the QSAR model was validated (Fig. 6) using the
correlation coefficient value, (r) 0.970 for training set (Fig. 6a)
and 0.985 for the test set (Fig. 6b). This shows the efficiency of
the model generated and the results clearly indicated that the com-
pound was predicted to be a potent anti-cancer agent. In particular,
THMPP correlates well with the equation, which substantiates its
toxic effect against cancer cells.
Further, the results of the ADMET analysis are shown in the
Table 2. The oral bioavailability and ADMET risk profiling were
within their acceptable limit for THMPP. It obeyed Lipinski rule
of five and had good absorption properties. Also, it is predicted to
cross the Blood Brain Barrier and has Caco-2 permeability and good
intestinal absorption and predicted to be localized in mitochondria
of the cell. The metabolism and toxicity parameters are also
acceptable for THMPP. The complete endpoints prediction con-
cludes that the compound THMPP, exhibits good drug likeliness
properties.
4. Discussion
Several studies are reported on various natural and synthetic
phenolics to have cytotoxic effect on cancer cells. (Liu et al.,
2018; LS et al., 2016; Spatafora and Tringali, 2012). Reports on
Fig. 6. QSAR Correlation plot. (a) Training set correlation coefficient (R2 = 0.970). (b) Test set correlation coefficient (R2 = 0.985).
Table 2
ADME and drug likeness properties of the ligand THMPP.
End Points HTS Data Accuracy
Blood-Brain Barrier BBB+ 0,8003
Human Intestinal Absorption HIA+ 0,9971
Caco-2 Permeability Caco2+ 0,5375
P-glycoprotein Substrate Non-substrate 0,7583
P-glycoprotein Inhibitor Non-inhibitor 0,6068
Non-inhibitor 0,9278
Renal Organic Cation Transporter Non-inhibitor 0,8148
Subcellular localization Mitochondria 0,6819
CYP450 2C9 Substrate Non-substrate 0,6246
CYP450 2D6 Substrate Non-substrate 0,8092
CYP450 3A4 Substrate Substrate 0,6311
CYP450 1A2 Inhibitor Inhibitor 0,7358
CYP450 2C9 Inhibitor Inhibitor 0,651
CYP450 2D6 Inhibitor Non-inhibitor 0,8645
CYP450 2C19 Inhibitor Non-inhibitor 0,5508
CYP450 3A4 Inhibitor Non-inhibitor 0,7413
CYP Inhibitory Promiscuity High CYP Inhibitory
Promiscuity
0,7253
Human Ether-a-go-go-Related Gene
Inhibition
Strong inhibitor 0,5167
Non-inhibitor 0,7336
AMES Toxicity AMES toxic 0,9402
Carcinogens Non-carcinogens 0,6772
Fish Toxicity High FHMT 0,9583
Tetrahymena Pyriformis Toxicity High TPT 0,9846
Honey Bee Toxicity Low HBT 0,513
Biodegradation Not ready biodegradable 0,9604
Acute Oral Toxicity Category III 0,7048
Carcinogenicity (Three-class) Warning 0,4551
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phenolic derivative like phenolic acids are available which deal
with anti-oxidant property and their action on cancer cell prolifer-
ation. Many dietry phenolic acids have also been tested. In partic-
ular, the well known phenolics, caffeic acid when treated with
breast cancer cells, T47D showed good growth inhibition with
the IC50 of 2.17  109 M (Kampa et al., 2004b). Phenolic com-
pounds which are structurally related have been also shown to
induce cell cycle arrest and apoptosis of cancer cells(Ahmad
et al., 2011) (Amawi et al., 2017).
The susceptible nature of tumor cells to apoptosis is the vital
determinant of chemotherapy efficacy (Stumm et al., 2004). Thus,
an effective anti-cancer drugs, which can target breast cancer cells
by inducing apoptosis is needed for efficient treatment. We deter-
mined the ability of THMPP to induce apoptosis in breast cancer
cells using DNA fragmentation analysis, Caspase3/9 activity assay,
FITC/Annexin staining and AO/EtBr fluorescent staining proce-
dures. It is evident that, THMPP induced apoptosis via caspase
3/9 activation, but then other signaling pathways might also be
induced along with caspase 3/9 activation. Therefore, further anal-
ysis of apoptosis and/or autophagy signaling pathway on multiple
cancer cell types should be implemented for anticancer
development.
On the other hand, expression of genes involved in the tumor
progression is altered in cancer conditions. PI3K/AKT/S6K1/mTOR
pathway promotes cell survival and cell proliferation, which is con-
tinuously over-expressed in breast cancer cells. In this study, the
newly synthesized THMPP was able to down regulate PI3K and
S6K1 genes, which could suppress proliferation and induce apopto-
sis. Also, decrease in the S6K1 expression reduces the risk of radi-
ation resistance of cancer cells(Tandon et al., 2011). This
attribute reduces the risk of side effects which are common in
chemotherapeutic agents. Similar researches were also carried
out in the well known polyphenols of green and black tea and were
reported to have anti-cancer properties by up- or down-regulating
a number of key enzymes (Beltz et al., 2006). Overall, THMPP was
identified to be a candidate drug to treat multiple breast cancer
and further clinical trials in animal model is essential to verify
the antitumor activity.
5. Conclusion
The present investigation revealed that THMPP can act as a
potential drug for treating breast cancer. This study demonstrated
that THMPP has cytotoxic activity on MCF-7 and SkBr3 breast can-
cer cell line. THMPP was determined to be apoptosis induced, trig-
gering DNA fragmentation as well as caspase 3/9 in human breast
cancer cell lines. Additionally, molecular docking of THMPP with
EGFR identified that the can potentially interact with EGFR and
activate its downstream signaling pathway. Gene expression anal-
ysis also confirms the downregulation of PI3K, suggesting that
THMPP might de-regulate the EGFR signaling pathway in breast
cancer cells. The QSAR and ADMET analysis also proves that
THMPP as non carcinogenic and a good drug-like candidate for
breast cancer treatment. Overall, we anticipate that THMPP can
be technically exploited further for the development of an effective
anti-breast cancer agents.
Author contributions
SP executed the experiments and data analysis. AK involved in
technical discussion and management. OY and MK conceived and
managed all studies. All the authors contributed to writing the
manuscript.
Ethical approval
This article does not contain any studies with human partici-
pants performed by any of the authors.
Acknowledgement
We would like to thank Prof. Nuno R. Candeias, Faculty of Engi-
neering and Natural Sciences, Tampere University for gift of syn-
thesized compounds.
Declaration of Competing Interest
The authors declare that they have no known competing finan-
cial interests or personal relationships that could have appeared to
influence the work reported in this paper.
References
Ahmad, A., Sakr, W.A., Rahman, K.W., 2011. Mechanisms and therapeutic
implications of cell death induction by indole compounds. Cancers (Basel) 3,
2955. https://doi.org/10.3390/CANCERS3032955.
Amawi, H., Ashby, C.R., Samuel, T., Peraman, R., Tiwari, A.K., Tiwari, A.K., 2017.
Polyphenolic nutrients in cancer chemoprevention and metastasis: role of the
epithelial-to-mesenchymal (EMT) pathway. Nutrients 9. https://doi.org/
10.3390/nu9080911.
Basikc, D., Papovic, S., Ristic, P., Arsenijevic, N., 2006. Analysis of cycloheximide-
induced apoptosis in human leukocytes: fluorescence microscopy using
annexin V/propidium iodide versus acridin orange/ethidium bromide. Cell
Biol. Int. 30, 924–932. https://doi.org/10.1016/j.cellbi.2006.06.016.
Basnakian, A.G., James, S.J., 1994. A rapid and sensitive assay for the detection of
DNA fragmentation during early phases of apoptosis. Nucleic Acids Res. 22,
2714–2715.
Beltz, L.A., Bayer, D.K., Moss, A.L., Simet, I.M., 2006. Mechanisms of cancer
prevention by green and black tea polyphenols. Anticancer. Agents Med.
Chem. 6, 389–406.
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A., Jemal, A., 2018. Global
cancer statistics 2018: GLOBOCAN estimates of incidence and mortality
worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68, 394–424.
https://doi.org/10.3322/caac.21492.
Chomzynski, P., Sacchi, N., 1987. Single-step method of RNA isolation by acid
guanidinium thiocyanate–phenol–chloroform extraction. Anal. Biochem. 162,
156–159. https://doi.org/10.1006/abio.1987.9999.
Chowdhury, S., Kandhavelu, M., Yli-Harja, O., Ribeiro, A.S., 2012. An interacting
multiple model filter-based autofocus strategy for confocal time-lapse
microscopy. J. Microsc. https://doi.org/10.1111/j.1365-2818.2011.03568.x.
Ciruelos Gil, E.M., 2014. Targeting the PI3K/AKT/mTOR pathway in estrogen
receptor-positive breast cancer. Cancer Treat. Rev. 40, 862–871. https://doi.
org/10.1016/j.ctrv.2014.03.004.
Doan, P., Musa, A., Candeias, N.R., Emmert-Streib, F., Yli-Harja, O., Kandhavelu, M.,
2019. Alkylaminophenol induces G1/S phase cell cycle arrest in glioblastoma
cells through p53 and cyclin-dependent kinase signaling pathway. Front.
Pharmacol. https://doi.org/10.3389/fphar.2019.00330.
Doan, P., Nguyen, T., Yli-Harja, O., Candeias, N.R., Kandhavelu, M., 2017. Effect of
alkylaminophenols on growth inhibition and apoptosis of bone cancer cells. Eur.
J. Pharm. Sci. 107, 208–216. https://doi.org/10.1016/j.ejps.2017.07.016.
El Molla, S.G., Motaal, A.A., El Hefnawy, H., El Fishawy, A., 2016. Cytotoxic activity of
phenolic constituents from Echinochloa crus-galli against four human cancer
cell lines. Brazilian J. Pharmacogn. https://doi.org/10.1016/j.bjp.2015.07.026.
Jones, G., Willett, P., Glen, R.C., Leach, A.R., Taylor, R., 1997b. Development and
validation of a genetic algorithm for flexible docking. J. Mol. Biol. https://doi.
org/10.1006/jmbi.1996.0897.
Kampa, M., Alexaki, V.-I., Notas, G., Nifli, A.-P., Nistikaki, A., Hatzoglou, A.,
Bakogeorgou, E., Kouimtzoglou, E., Blekas, G., Boskou, D., Gravanis, A.,
Castanas, E., 2004b. Introduction Antiproliferative and apoptotic effects of
selective phenolic acids on T47D human breast cancer cells: potential
mechanisms of action. https://doi.org/10.1186/bcr752.
Karjalainen, A., Yli-Harja, O., Kandhavelu, M., Doan, P., Candeias, N.R., Sandberg, O.,
Chandraseelan, J.G., 2017. Synthesis of phenol-derivatives and biological
screening for anticancer activity. Anticancer. Agents Med. Chem. 17, 1710–
1720. https://doi.org/10.2174/1871520617666170327142027.
Kato, S., Endoh, H., Masuhiro, Y., Kitamoto, T., Uchiyama, S., Sasaki, H., Masushige, S.,
Gotoh, Y., Nishida, E., Kawashima, H., Metzger, D., Chambon, P., 1995. Activation
of the estrogen receptor through phosphorylation by mitogen-activated protein
kinase. Science 270, 1491–1494.
Koopman, G., Reutelingsperger, C.P., Kuijten, G.A., Keehnen, R.M., Pals, S.T., van Oers,
M.H., 1994. Annexin V for flow cytometric detection of phosphatidylserine
expression on B cells undergoing apoptosis. Blood 84, 1415–1420.
502 S. Palanivel et al. / Saudi Pharmaceutical Journal 28 (2020) 495–503
Liu, J., Ming, B., Gong, G.-H., Wang, D., Bao, G.-L., Yu, L.-J., 2018. Current
research on anti-breast cancer synthetic compounds. https://doi.org/10.1039/
c7ra12912b.
Ls, R., Nja, S., Ncp, S., Mc, M., Aj, T., 2016. Anticancer properties of phenolic acids in
colon cancer – a review. J. Nutr. Food Sci. 06, 1–7. https://doi.org/10.4172/2155-
9600.1000468.
Malek, S.N.A., Wahab, N.A., Yaacob, H., Shin, S.K., Lai, H.S., Serm, L.G., Rahman, S.N.S.
A., 2008. Cytotoxic Activity of Pereskia bleo (Cactaceae) Against Selected
Human Cell Lines. Int. J. Cancer Res. 4, 20–27. https://doi.org/10.3923/
ijcr.2008.20.27.
Manikandan, S., Malik, B.K., 2008. Modeling of human CCR5 as target for HIV-I and
virtual screening with marine therapeutic compounds. Bioinformation 3, 89–
94.
Martelli, A.M., Chiarini, F., Evangelisti, C., Grimaldi, C., Ognibene, A., Manzoli, L., Billi,
A.M., McCubrey, J.A., 2010. The phosphatidylinositol 3-kinase/AKT/mammalian
target of rapamycin signaling network and the control of normal myelopoiesis.
Histol. Histopathol. 25, 669–680. https://doi.org/10.14670/HH-25.669.
Mosmann, T., 1983. Rapid colorimetric assay for cellular growth and survival:
application to proliferation and cytotoxicity assays. J. Immunol. Methods 65,
55–63.
Nissink, J.W.M., Murray, C., Hartshorn, M., Verdonk, M.L., Cole, J.C., Taylor, R., 2002.
A new test set for validating predictions of protein-ligand interaction. Proteins
Struct. Funct. Bioinforma. 49, 457–471. https://doi.org/10.1002/prot.10232.
Roy, K., Kar, S., Das, R.N., Roy, K., Kar, S., Das, R.N., 2015. Validation of QSAR models.
Underst. Basics QSAR Appl. Pharm. Sci. Risk Assess., 231–289 https://doi.org/
10.1016/B978-0-12-801505-6.00007-7.
Sawadogo, W.R., Le Douaron, G., Maciuk, A., Bories, C., Loiseau, P.M., Figadère, B.,
Guissou, I.P., Nacoulma, O.G., 2012. In vitro antileishmanial and
antitrypanosomal activities of five medicinal plants from Burkina Faso.
Parasitol. Res. 110, 1779–1783. https://doi.org/10.1007/s00436-011-2699-3.
Spatafora, C., Tringali, C., 2012. Natural-derived polyphenols as potential anticancer
agents. Anticancer. Agents Med. Chem. 12, 902–918. https://doi.org/10.2174/
187152012802649996.
Stumm, S., Meyer, A., Lindner, M., Bastert, G., Wallwiener, D., Gückel, B., 2004.
Paclitaxel treatment of breast cancer cell lines modulates fas/fas ligand
expression and induces apoptosis which can be inhibited through the CD40
receptor. Oncology 66, 101–111. https://doi.org/10.1159/000077435.
Sun, M., Paciga, J.E., Feldman, R.I., Yuan, Z., Coppola, D., Lu, Y.Y., Shelley, S.A., Nicosia,
S.V., Cheng, J.Q., 2001. Phosphatidylinositol-3-OH kinase (PI3K)/AKT2, activated
in breast cancer, regulates and is induced by estrogen receptor (ER) via
interaction between ER and PI3K 1. Cancer Res. 61, 5985–5991.
Tandon, P., Gallo, C.A., Khatri, S., Barger, J.F., Yepiskoposyan, H., Plas, D.R., 2011.
Requirement for ribosomal protein S6 kinase 1 to mediate glycolysis and
apoptosis resistance induced by Pten deficiency. Proc. Natl. Acad. Sci. U.S.A. 108,
2361–2365. https://doi.org/10.1073/pnas.1013629108.
Tao, L.Y., Zhang, J.Y., Liang, Y.J., Chen, L.M., Zheng, L.S., Wang, F., Mi, Y.J., She, Z.G., To,
K.K.W., Lin, Y.C., Fu, L.W., 2010. Anticancer effect and structure-activity analysis
of marine products isolated from metabolites of mangrove fungi in the South
China Sea. Mar. Drugs. https://doi.org/10.3390/md8041094.
Todeschini, R., Gramatica, P., 1997. 3D-modelling and Prediction by WHIM
descriptors. Part 6. Application of WHIM descriptors in QSAR studies. Quant.
Struct. Relationships 16, 120–125. https://doi.org/10.1002/qsar.19970160204.
Vaiyapuri, P.S., Ali, A.A., Mohammad, A.A., Kandhavelu, J., Kandhavelu, M., 2015.
Time lapse microscopy observation of cellular structural changes and image
analysis of drug treated cancer cells to characterize the cellular heterogeneity.
Environ. Toxicol. 30, 724–734. https://doi.org/10.1002/tox.21950.
Vermes, I., Haanen, C., Steffens-Nakken, H., Reutelingsperger, C., 1995. A novel assay
for apoptosis. Flow cytometric detection of phosphatidylserine expression on
early apoptotic cells using fluorescein labelled Annexin V. J. Immunol. Methods
184, 39–51.
S. Palanivel et al. / Saudi Pharmaceutical Journal 28 (2020) 495–503 503
